孟加拉国农村地区戊型肝炎疫苗接种与胎儿丢失:一项双盲、整群随机对照试验的进一步分析
该研究对戊型肝炎疫苗HEV239有效性试验中的妊娠参与者进行安全性信号分析。在孟加拉国Matlab的67个村庄中,非妊娠16-39岁女性随机接种HEV239或乙型肝炎疫苗。结果显示,在末次月经前90天至妊娠结局期间接种HEV239者,流产风险较对照组升高(aRR 2.0)。结论认为妊娠前不久或妊娠期间接种HEV239与流产风险升高相关。
要点
- 近LMP期接种HEV239者流产54/607(8.9%),对照组32/719(4.5%),aRR 2.0(95%CI 1.3-3.1)。
- 妊娠期间意外接种HEV239者流产22/209(10.5%),对照组14/266(5.3%),aRR 2.1(95%CI 1.1-4.1)。
- 远LMP期接种HEV239者流产风险未显著升高(aRR 1.3,95%CI 0.8-1.9)。
核心结论
- 妊娠前不久或妊娠期间接种HEV239与流产风险升高相关,对育龄女性程序性使用HEV239构成可能的安全性关注。
研究设计与样本
- 双盲、整群随机对照试验的进一步分析,孟加拉国Matlab的67个村庄按1:1随机分配至HEV239组或Hepa-B对照组,纳入16-39岁非妊娠女性19460名,其中5011名在接种后2年内妊娠并符合分析标准(HEV239组2407名,对照组2604名)。
主要发现
- 近LMP期接种并评估流产者中,HEV239组流产54/607(8.9%),对照组32/719(4.5%),aRR 2.0(95%CI 1.3-3.1),p=0.0009。
- 妊娠期间意外接种者中,HEV239组流产22/209(10.5%),对照组14/266(5.3%),aRR 2.1(95%CI 1.1-4.1),p=0.036。
- LMP前90天内接种者中,HEV239组流产32/398(8.0%),对照组18/453(4.0%),aRR 1.9(95%CI 1.1-3.2),p=0.013。
- 远LMP期接种者中,HEV239组流产93/1647(5.6%),对照组80/1773(4.5%),aRR 1.3(95%CI 0.8-1.9),p=0.295,未观察到流产风险升高。
- 在任何分析期,HEV239组与Hepa-B组相比,死产和选择性终止妊娠均未显示风险升高。
临床怎么用
- 作者认为,妊娠前不久或妊娠期间接种HEV239与流产风险升高相关,对育龄女性程序性使用HEV239构成可能的安全性关注。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccination constitutes an attractive control measure for hepatitis E virus (HEV), a major cause of maternal and perinatal mortality globally. Analysis of pregnant participants in an effectiveness trial of the HEV vaccine HEV239 showed possible HEV239-associated fetal losses. We aimed to conduct a detailed analysis of this safety signal. METHODS: In a double-blind, cluster-randomised trial, 67 villages in Matlab, Bangladesh, were randomly allocated (1:1) to two vaccine groups, in which non-pregnant women aged 16-39 years received either HEV239 (HEV239 group) or Hepa-B (a hepatitis B vaccine; control group). We implemented weekly surveillance for pregnancy detection, and follow-up of pregnancies once every 2 weeks, using physician-confirmed diagnoses to evaluate fetal loss outcomes (miscarriage [spontaneous abortion], stillbirth, and elective termination). Data from a parallel system of reproductive health surveillance in Matlab were used to clarify study diagnoses when necessary. Miscarriage was assessed only among participants whose first positive pregnancy test and vaccination date (for whichever dose was closest to the date of last menstrual period [LMP]) were before 20 weeks' gestation. We defined the following analysis periods of interest: from 90 days before the LMP until the pregnancy outcome (the proximal period); from the LMP date until the pregnancy outcome (the pregnancy period); from 90 days before the LMP until the LMP date (90 days pre-LMP period); and from enrolment until 90 days before the LMP (the distal period). Both Poisson and Cox regression models were used to assess the associations between receipt of HEV239 and fetal loss outcomes. The trial was registered with ClinicalTrials.gov (NCT02759991). FINDINGS: Among the 19 460 non-pregnant participants enrolled in the trial, 5011 were identified as having pregnancies within 2 years following vaccination and met the criteria for analysis (2407 in the HEV239 group and 2604 in the control group). Among participants vaccinated in the proximal period and evaluated for miscarriage, miscarriage occurred in 54 (8·9%) of 607 in the HEV239 group and 32 (4·5%) of 719 in the control group (adjusted relative risk [aRR] 2·0 [95% CI 1·3-3·1], p=0·0009). Similarly, the risk of miscarriages was increased in the HEV239 group versus the control group among participants inadvertently vaccinated during pregnancy (22 [10·5%] miscarriages among 209 participants in the HEV239 group vs 14 [5·3%] of 266 in the control group; aRR 2·1 [95% CI 1·1-4·1], p=0·036) and among those vaccinated within 90 days pre-LMP (32 [8·0%] of 398 vs 18 [4·0%] of 453; 1·9 [1·1-3·2], p=0·013). No increased risk of miscarriage was observed in those who received HEV239 in the distal period (93 [5·6%] of 1647 vs 80 [4·5%] of 1773; 1·3 [0·8-1·9], p=0·295). Stillbirth and elective termination showed no increased risk among women administered HEV239 versus those administered Hepa-B in any of the analysis periods. INTERPRETATION: HEV239 given shortly before or during pregnancy was associated with an elevated risk of miscarriage. This association poses a possible safety concern for programmatic use of HEV239 in women of childbearing age. FUNDING: Research Council of Norway and Innovax.
引用
- Aziz AB, Dudman S, Julin CH, et al. Receipt of hepatitis E vaccine and fetal loss in rural Bangladesh: further analysis of a double-blind, cluster-randomised, controlled trial. Lancet Glob Health. 2024. PMID: 39030061. doi:10.1016/S2214-109X(24)00193-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。